Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
There are many limitations in the current treatments of Inflammatory bowel disease (IBD). Now
the investigators realized that the intestinal microecological is closely associated with the
development of IBD. So the standardized fecal microbiota transplantation is considered to be
simple but effective emerging therapies for the treatment of IBD. In this project the
investigators intend to carry out a single-center, randomized, single-blind clinical
intervention study. The investigators will recruit 40 patients with IBD (20 cases of
Ulcerative Colitis and 20 cases of Crohn's disease) in China. The patients will be randomly
divided into 2 groups, one group will be given treatment of standardized fecal microbiota
transplantation, the other will be simply treated with mesalazine, followed up for at least 1
year. The investigators propose to determine the efficiency, durability and safety of
Standardized Fecal Microbiota Transplantation for IBD treatment.